ES3034835T3 - Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion - Google Patents

Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion

Info

Publication number
ES3034835T3
ES3034835T3 ES23730718T ES23730718T ES3034835T3 ES 3034835 T3 ES3034835 T3 ES 3034835T3 ES 23730718 T ES23730718 T ES 23730718T ES 23730718 T ES23730718 T ES 23730718T ES 3034835 T3 ES3034835 T3 ES 3034835T3
Authority
ES
Spain
Prior art keywords
annexin
protein
monomeric
subject
retinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES23730718T
Other languages
English (en)
Spanish (es)
Inventor
Anna Frostegård
Anders Haegerstrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annexin Pharmaceuticals AB
Original Assignee
Annexin Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2207263.1A external-priority patent/GB202207263D0/en
Application filed by Annexin Pharmaceuticals AB filed Critical Annexin Pharmaceuticals AB
Application granted granted Critical
Publication of ES3034835T3 publication Critical patent/ES3034835T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES23730718T 2022-05-18 2023-05-18 Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion Active ES3034835T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2207263.1A GB202207263D0 (en) 2022-05-18 2022-05-18 Therapeutic compositions
PCT/EP2023/063441 WO2023227468A1 (fr) 2022-05-18 2023-05-18 Annexine a5 monomère pour une utilisation dans le traitement de l'oedème maculaire ou d'une occlusion d'une veine rétinienne

Publications (1)

Publication Number Publication Date
ES3034835T3 true ES3034835T3 (en) 2025-08-25

Family

ID=96808785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES23730718T Active ES3034835T3 (en) 2022-05-18 2023-05-18 Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion

Country Status (3)

Country Link
US (1) US20250339491A1 (fr)
CA (1) CA3253955A1 (fr)
ES (1) ES3034835T3 (fr)

Also Published As

Publication number Publication date
US20250339491A1 (en) 2025-11-06
CA3253955A1 (fr) 2023-11-30

Similar Documents

Publication Publication Date Title
JP7791125B2 (ja) 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
ES3059190T3 (en) Treatment of ocular disease
ES3041647T3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
ES2886542T3 (es) Uso de sirolimus para tratar la degeneración macular asociada con la edad exudativa con edema persistente
KR20230106598A (ko) 겔 제형과 같은 맥락막위 투여용 제형
AU2020230409A1 (en) Method for the treatment of a disease using pigment epithelium-derived factor (PEDF)
KR20220062279A (ko) 안질환의 치료 방법
US20230054032A1 (en) Compositions and methods for treating ocular disease
ES3034835T3 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
EP4429693B1 (fr) Annexine a5 monomère pour une utilisation dans le traitement de l'oedème maculaire ou d'une occlusion d'une veine rétinienne
HK40115628B (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK40115628A (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
AU2024272228A1 (en) Annexin a5 protein as a combination therapy with an anti-vegf agent for use in the treatment of macular oedema or retinal vein occlusion
EA051980B1 (ru) Расширенные схемы применения высоких доз антагониста vegf для лечения ангиогенных нарушений со стороны глаза
Mamane Retinitis pigmentosa-associated cystoid macular oedema
TW202122419A (zh) 以全人類轉譯後修飾之抗VEGF Fab治療糖尿病性視網膜病變
HK40052983A (zh) 含有高浓度vegf受体融合蛋白的制剂
EA046718B1 (ru) Составы, содержащие слитый белок рецептора фрэс в высокой концентрации